Select Language:
Weight-loss injections that have gained popularity for their role in helping individuals shed pounds may also offer a glimmer of hope for some patients with advanced cancer, specifically those whose disease has spread to the brain, according to a recent study.
These medications fall under the category of GLP-1 receptor agonists, including drugs like Wegovy and Ozempic. Originally designed to treat type 2 diabetes, they have captured international attention over recent years because many users report significant weight loss.
The new research does not demonstrate that these injections directly combat cancer. Instead, it suggests a potentially important and more subtle benefit: they could help certain severely ill patients extend their lifespan.
The focus of the study was on brain metastases, which occur when cancer cells migrate from other parts of the body—such as the lungs, breasts, or skin—and form tumors in the brain. Unfortunately, brain metastases are common and often indicate that cancer has reached a late and dangerous stage.
Many patients in this situation also contend with type 2 diabetes. This comorbidity complicates treatment, as high blood sugar levels can cause chronic inflammation, damage blood vessels, and weaken the body’s ability to manage illness effectively.
In clinical practice, steroids are frequently prescribed to help manage symptoms like brain swelling. While steroids are effective, they tend to raise blood sugar levels and can make diabetes more challenging to control. This has prompted researchers to explore whether GLP-1 drugs might offer additional benefits beyond blood sugar regulation.
Laboratory studies suggest these drugs might protect brain cells, reduce inflammation, and help maintain healthy blood flow to the brain. However, until now, real-world clinical data on how patients with both diabetes and brain metastases fare when taking these medications has been limited.
To address this, researchers examined a database of anonymized health records from 151 hospitals and healthcare systems worldwide, covering patients from 2018 to 2024. They focused on adults with three conditions: cancer, type 2 diabetes, and brain metastases. A key aspect of the study was identifying whether these patients had been prescribed a GLP-1 medication—like semaglutide, dulaglutide, liraglutide, or tirzepatide—around the time they were diagnosed with both diabetes and brain metastases.
The team matched patients who received these medications with similar individuals who did not, controlling for variables such as age, gender, cancer type, other health conditions, and treatments like chemotherapy, radiation, or steroids. This reduces biases and allows for more reliable comparisons.
In total, the analysis included over 19,000 patients with cancer, brain metastases, and type 2 diabetes. Among these, 866 had been treated with a GLP-1 drug, while more than 11,000 had not. After matching, the study compared two groups of 850 patients each, with comparable health profiles and cancer types.
The patients were followed for up to three years after their brain metastases diagnosis. The primary question was straightforward: what proportion of each group died during this period?
The findings indicated that patients on GLP-1 medications had a significantly lower risk of mortality compared to those not on these drugs. Overall, the group taking GLP-1 drugs was approximately 37% less likely to die over the three-year span.
This trend was consistent across various major cancer types, including lung, breast, and melanoma. Interestingly, the improved survival was observed not only with GLP-1 drugs but also when compared with other modern diabetes medications like SGLT2 inhibitors and DPP-4 inhibitors. This suggests that there might be something specific about the action of GLP-1 signaling that confers a benefit, beyond just controlling blood sugar.
However, the researchers emphasized that the study has limitations. Since it’s a retrospective analysis using medical records, it cannot establish causation. Randomized controlled trials, where patients are assigned to treatments and followed prospectively, are needed to confirm these findings.
So how might GLP-1 drugs help patients whose cancer has spread to the brain? One possibility is that their benefits are indirect—improving diabetes management, reducing body weight, and supporting cardiovascular health could enable patients to better tolerate cancer treatments like surgery, radiation, or chemotherapy.
Another intriguing possibility is that these drugs may exert more direct effects on the brain. GLP-1 receptors are present in brain tissue and are involved in regulating inflammation, protecting nerve cells, and maintaining the integrity of the blood–brain barrier—a protective layer that shields the brain from harmful substances. Animal studies suggest that activating these receptors can reduce brain cell damage and improve their function, potentially creating a less hospitable environment for metastatic tumors.
Nevertheless, these mechanisms are still speculative in humans, and more research is necessary to clarify how GLP-1 drugs might influence brain metastases.
For patients and families reading about this research, it’s vital to understand that these findings do not mean that individuals with brain metastases should start taking GLP-1 medications immediately or that these drugs can replace standard cancer treatments such as radiation, surgery, or immunotherapy. Currently, the evidence is preliminary, and any treatment decisions should be made in consultation with healthcare providers.
It’s important to note that these drugs are primarily used for diabetes and weight loss in people who already have that condition. Like all medications, they can cause side effects, including nausea and vomiting, and rare but serious risks are associated with their use. Patients considering them should do so under the careful guidance of their medical team.
If future clinical trials confirm the survival benefits observed, GLP-1 medications might become part of supportive care strategies for patients battling brain metastases and diabetes, opening up a promising new avenue of research intersecting metabolism and cancer treatment.
For additional insights on weight loss and health, explore studies about potential dietary aids like oranges for obesity and berries for preventing cancer, diabetes, and obesity. Also, check out recent research on ginger’s role in weight management and green tea’s potential benefits for weight loss.
Written by Justin Stebbing, published in The Conversation.
ChatGPT
Perplexity
Gemini AI
Grok AI
